Kornimate/medical-research-clean huggingface dataset:
assessment of stent strut coverage and endothelial function after drug-eluting stents

Conditions: Coronary Artery Disease; Atherosclerosis

Summary: the purpose of this study is to compare coronary endothelium function in patients with a zotarolimus-eluting versus a sirolimus-eluting or a everolimus-eluting stents with optical coherence tomography, vasoconstriction in response to acetylcholine, and coronary biomarker level.


Eligibility criteria:
inclusion criteria: * significant coronary de novo lesion (\> 70% by quantitative angiographic analysis) * patients with stable or acute coronary syndrome considered for coronary revascularization * reference vessel diameter of 2.5 to 3.5 mm by operator assessment exclusion criteria: * contraindication to anti-platelet agents * ostial lesion within 5 mm from ostium * different des in other vessel simultaneously * creatinine level 2.5 mg/dl * left main stenosis more than 50%. * vein graft lesion * triple vessel disease with stenosis more than 50% in 3 epicardial coronary arteries * life expectancy 1 year * reference vessel \ 4.0 mm diameter by visual * long lesion that require more than three stents
bariatric surgery and male reproductive function

Conditions: Obesity; Diabetes Mellitus, Type 2; Bariatric Surgery Candidate; Roux en Y Gastric Bypass; Sleeve Gastrectomy

Summary: obesity is a global public health problem. according to literature reports, as of 2016, china's obese population has reached more than 90 million and type 2 diabetes mellitus has reached more than 100 million, which has brought a serious health and economic burden to china. in addition to various health problems such as cardiovascular, osteoarthritis, and tumors, obesity can also cause abnormalities in reproductive endocrine. in women, it can cause abnormal menstruation, polycystic ovary syndrome, and male obesity can cause secondary gonadal. hypofunction (mosh). mosh is an endocrine dysfunction. it is reported to have a prevalence of approximately 45% in moderate to severe obesity. in addition, studies have pointed out that the prevalence of hypogonadism in men with type 2 diabetes and obesity higher. however, there are no studies on the reproductive function of chinese male patients after bariatric surgery. pre- and post-operative semen will be collected for analysis to observe the effect of bariatric surgery on male reproductive function.


Eligibility criteria:
inclusion criteria: * meet the surgical indications according to the chinese guidelines for surgical treatment of obesity and type 2 diabetes (2019 edition). * 20 years old\< patient\<60 years old. * male exclusion criteria: * incapacity of giving an informed consent. * drug and / or alcohol abuse. * scrotal injury and previous scrotal surgery. * use of phosphodiesterase-5 inhibitors. * mental illnesses that may affect compliance with clinical research, including dementia, active psychosis, major depression, or attempted suicide.

Keywords: semen micronutrient inflammation nutrition
evaluation of vaginal self-sampling diagnostic performances to identify genital infections

Conditions: Genital Infection; Asymptomatic Infections

Summary: screening for genital infection (gi), sexually transmitted infection (sti) and asymptomatic carriage of group b streptococcus (gbs) in pregnant women is a common reason for medical appointments. conventional testing is performed by using vaginal and/or cervical classic sampling (vcs). vaginal self-sampling (vss) has progressively emerged as an alternative to vcs for sti agent screening. the use of vaginal self-sampling (vss) could facilitate follow-ups and potentially help in the prevention of gynaecological disorders.


Eligibility criteria:
inclusion criteria: * women requiring vaginal or cervical classical sampling to screen for genital infections * women requiring vaginal or cervical classical sampling to screen for sexually transmitted infections (sti) * pregnant women requiring vaginal classical sampling to screeen for group b streptococcus asymptomatic carriage in the eighth month of pregnancy * informed written consent from the patient exclusion criteria: * person subjected to therapeutic limitation decision * women with intact hymen * active antibiotic or antifungic treatment * antiobiotic or antifungic treatment during the 10 days prior to inclusion

Keywords: vaginal self-sampling sti genital infection group b streptococcus
association between child's psychological resilience and practicing oral habits

Conditions: Oral Habits

Summary: the aim of the present study is to determine the effect of psychological resilience on practicing oral habits among a group of 5- to 7-year-old children.

psychological pressure has been thought to be a predisposing factor that might result in deleterious oral habits practicing. shahraki et al. stated that increased stress levels are associated with oral habits as thumb sucking and nail biting. leme et al. concluded that children and adolescents with doh presented more symptoms of depression than their counterparts. moreover, they were more likely to report symptoms of anxiety. ability to cope (or resilience) includes a person's sense of agency and their ability to think and behave, to make positive decisions, and to apply skills and knowledge to life challenges. the term resilience has come to mean an individual's ability to overcome adversity and continue his or her normal development. the association between psychological resilience and practicing oral habits in children remains unclear, this study aims to reveal that association, if present.

Eligibility criteria:
inclusion criteria: * medically free children exclusion criteria: -
coenzyme q10 in older athletes treated with statin medications

Conditions: Muscle Weakness; Myalgia; Side Effects of Statins

Summary: the purpose of this study is to evaluate the effect of coenzyme q10 administration in improving mitochondrial function as measured by anaerobic threshold in older athletes on a stable dose of statin medication.


Eligibility criteria:
inclusion criteria: * patients ≥ 50 years of age, male or female. * patients on a stable dose of statin medication for at least 3 months prior to enrollment in the study * self-described athletes with any of the following characteristics: * participation in a competitive athletic event within the past year or currently training for a competitive athletic event within the 6 months following enrollment * regular exercise activity of at least 45 minutes duration 5 times per week exclusion criteria: * use of coenzyme q10 during the preceding two months. * cpk level at baseline greater than two times the upper limits of normal * ldl level at baseline greater than 160 for those without a cardiovascular risk or cardiovascular risk equivalent * ldl level at baseline greater than 130 for those with a cardiovascular risk or cardiovascular risk equivalent

Keywords: coenzyme q10 statins myalgias anaerobic threshold athletic performance
study of the use of laser light to treat osteoarthritis of the hand.

Conditions: Osteoarthritis

Summary: the purpose of this study is to determine whether low level light therapy is effective in the treatment of osteoarthritis of the hand, when the treatment is applied to the hand by an individual in his or her own home.

osteoarthritis of the hand is a disease that breaks down the cartilage and causes formation of new bone around the joints of the hand, resulting in pain, discomfort, and often lowered ability to move the affected joints. existing methods of treatment for osteoarthritis of the hand include oral and topical medications, physical therapy, occupational therapy, assistive device use, braces and surgery. this study is intended to evaluate the effectiveness of at-home use of a low level laser device in reducing the symptoms of osteoarthritis of the hand. comparison(s): active low level laser units in addition to rescue pain medication, compared to non-active ('fake') low level laser units in addition to rescue pain medication.

Eligibility criteria:
inclusion criteria: * clinical and radiographic diagnosis of osteoarthritis of the hand. * hand symptoms such as pain, aching and stiffness present across the prior six months. * willingness to use only tylenol to relieve hand symptoms during the study. * primary spoken language is english. exclusion criteria: * current use of narcotics, opiates, morphine, steroids. * previous surgery to the hand. * infection or wound in the hand. * involvement in litigation, worker's compensation claim or receiving disability benefits because of osteoarthritis of the hand. * participation in a research study during the prior 90 days. * pregnant or lactating.

Keywords: osteoarthritis hand laser device hand pain stiffness
ivermectin vs. placebo for the treatment of patients with mild to moderate covid-19

Conditions: COVID-19

Summary: ivermectin which is an fda-approved broad spectrum anti-parasitic agent, has also anti-viral activity. in vitro study have shown its activity against sars-cov-2, however its clinical effect on patients with covid-19 never been tested. in this rct we would like to evaluate the effect of ivermectin on reduction of viral shedding among mild to moderate covid-19 patients, and in shortening the symptom resolution time.


Eligibility criteria:
inclusion criteria: participants eligible for inclusion will include non-pregnant adult (\>18 years old) with molecular confirmation of covid-19. \[participants will be eligible in a period of no longer than 72 hours after exposure\]. exclusion criteria: * severe infection ( defined as need for invasive or non-invasive ventilator support, ecmo or shock requiring vasopressor support). * weight below 40kg or above 100kg * unable to take oral medication * known allergy to the drugs * pregnancy or breast feeding * participating in another rct for treatment of covid-19.
neoadjuvant immunotherapy plus chemotherapy in borrmann type 4 and large type 3 gastric cancer

Conditions: Stomach Neoplasms; Gastric Cancer; Linitis Plastica of Stomach

Summary: the aim of this study is to test the efficacy and safety of immunotherapy plus chemotherapy on people with a relatively rare type of gastric cancer. participants will take the anti-pd-1 inhibitor (tislelizumab) and platinum-based chemotherapy (oxaliplatin + capecitabine or oxaliplatin + s-1) in a 3-week cycle, followed by a radical operation after 6 cycles.


Eligibility criteria:
inclusion criteria: * histologically confirmed gastric adenocarcinoma,ct1-2n+m0 or ct3-4nanym0; * males or females, aged 18-70 years; * gastroscopy and abdominal computed tomography (ct) scan-confirmed typical scirrhous gastric cancer (borrmann type 4) or large type 3 (over 8 cm); * no peritoneal metastasis confirmed by laparoscopic exploration and with cytological examination of peritoneal washing of the douglas pouch; * ecog performance status 0 or 1; * sufficient organ function: * white blood cell count \> 4\*10\^9/l, neutrophil cell count \> 1.5\*10\^9/l, hemoglobin \> 90 g/l, platelet count \> 100\*10\^9 /l * serum bilirubin ≤ 1.5×upper limit of normal (uln), ast, alt ≤ 2.5×uln * creatinine ≤ 1.5 ×uln or serum clearance \> 60 ml/min * inr and aptt ≤ 1.5 × uln, only for subjects not receiving anticoagulant therapy;subjects undergoing coagulation therapy should use a stable dose * no prior anti-tumor therapy; * have signed informed consent before the beginning of treatment. exclusion criteria: * history of another malignancy within the last five years; * previous cytotoxic chemotherapy, radiotherapy or immunotherapy * unable to take drugs orally * allergic to to any drug of the study regimen; * women who are pregnant or breastfeeding or may be pregnant
substance use disorders and tobacco habits

Conditions: Substance Use Disorders

Summary: in the department for substance use disorders at uppsala university hospital there are two wards. one that is locked, where the patients that are emitted can not go out to smoke and another ward where there is a possibility to go out and smoke during the day. the smoking habits on those two floors will be compared and how they feel about smoking will be evaluated when they are admitted to the ward, at discharge, after 1 mont and after 6 months.

in the department for substance use disorders at uppsala university hospital there are two wards. one that is locked, where the patients that are emitted can not go out to smoke and another ward where there is a possibility to go out and smoke during the day. the smoking habits on those two wards will be compared and how they feel about smoking will be evaluated when they are admitted to the ward, at discharge, after 1 mont and after 6 months. the questionnaires that will be used for evaluation are: fagerstöms test for nicotine dependence, alcohol use disorders identification test and drug use disorders identification test and the symptoms of tobacco withdrawal mentioned in dsm-v. parameters that will be measured are: pulse, bloodpressure, peak expiratory flow, wight and height. there will also be some questions about their smoking and snuff habits, if they have tried to quite smoking before and how they were affected by the stop.

Eligibility criteria:
inclusion criteria: substance use disorder - exclusion criteria: disorganization, psychosis and if you can not speak swedish. -

Keywords: tobacco use, withdrawal symptoms
microalbuminuria as a cardiovascular risk factor (precised substudy)

Conditions: Microalbuminuria; Endothelial Dysfunction; Diabetic Nephropathy; Diabetic Retinopathy

Summary: microalbuminuria (ma) is an independent cardiovascular risk factor in diabetic and non-diabetic subjects. however, in the setting of type 2 diabetes, microalbuminuria could be a marker of either early diabetic nephropathy or diffuse endothelial dysfunction. at present, there are no biomarkers that permit us to discriminate between these two conditions.

a hypothesis free approach by using proteomic/metabolomic analyses in the urine samples of selected populations seems an appropriate approach by which to explore this issue. in addition, a driven hypothesis in the same groups of patients based on a sensitive marker of kidney injury also seems appropriate. urinary levels of kim-1(kidney injury molecule-1 ) have been found elevated in experimental diabetic nephropathy even before that ma . in addition, urinary levels of kim-1 were found significantly elevated in type 1 diabetic patients with ma, in comparison with diabetics with normoalbuminuria and non-diabetic healthy controls. moreover, low urinary kim-1 levels at baseline were associated with the regression of ma during a follow-up of 2 years . therefore, it could be hypothesized that the presence of ma + kim-1 in urine samples would indicate renal injury rather than endothelial dysfunction.

Eligibility criteria:
inclusion criteria: * adult patients with diabetes mellitus type 2 with microalbuminuria with and without retinopathy. control groups: diabetes mellitus type 1 with microalbuminuria and retinopathy hypertensive patients with microalbuminuria and diabetic patients with a renal biopsy exclusion criteria: * patients without microalbuminuria or patients with macroalbuminuria

Keywords: type 1 diabetic type 2 diabetic hypertension renal injury diabetic retinopathy
mflot chemotherapy as first-line treatment in gc

Conditions: Gastric Cancer

Summary: a single center phase 1b/2 trail to identified suitable dosage and its efficacy of modified flot regime in chinese gastric cancer patients. this trial is designed to identified recommended phase ii dose (rp2d) of modified flot in chinese patients, and to evaluate the efficacy of modified flot regime as first-line for advanced or metastatic gastric cancer. this trial is in 2 stages: the first stage will establish the maximum tolerated dose (mtd) and rp2d of docetaxel and oxaliplatin in flot regime. in the second stage, the efficacy of modified flot will be assessed by response rate.

the rp2d of flot regime will be established with a standard 3+3 design, starting with the dose of 40mg/m2 docetaxel (dose level 1) and 65mg/m2 oxaliplatin (dose level 1). the plan of dose escalation will be found in following table. chemotherapy will be administered two-weekly (maximum 12 cycles) until progression of disease, intolerable toxicity or withdraw of patients.

Eligibility criteria:
inclusion criteria: 1. male/female patients aged from 18 to 75 years. 2. histologically confirmed gastric adenocarcinoma. 3. gastric tumors should be treatment naïve unresectable or metastatic disease, or recurrence over 6 months after finish of adjuvant chemotherapy. 4. at least one measurable lesion should be confirmed by imaging examination. 5. ecog performance status 0 or 1 6. adequate bone marrow function: absolute neutrophil count (anc) ≥1.5x109/l white blood count ≥3.5x109/l platelets ≥80x109/l hemoglobin (hb) ≥90g/l (can be post-transfusion) 7. adequate renal function: creatinine clearance of \>50ml/min 8. adequate liver function: serum bilirubin \<22 umol/l alt/ast ≤2.5x uln, for patient with liver metastasis alt/ast ≤5x uln 10. adequate coagulation profile international normalised ratio (inr) \< 1.5 activated prothrombin time (aptt) \< 1.5xuln 11. without brain metastasis and peripheral nerve diseases 12. willingness and ability to comply with the protocol for the duration of the study including scheduled visits, examinations, investigations and treatment plans with informed consent form. exclusion criteria: 1. with second primary malignant diseases 2. any contraindication or known hypersensitivity reaction to any of the study drugs, or components of leucovorin, oxaliplatin, 5-fu or docetaxel 3. with uncontrollable complications 4. inadequate organ function 5. pregnancy or of child bearing potential.
68-ga-rm2 pet/mri in imaging patients with estrogen receptor-positive breast cancer

Conditions: Breast Carcinoma; Estrogen Receptor Positive

Summary: this trial studies how well 68-ga rm2 works with pet/mri in imaging patients with estrogen receptor-positive breast cancer. 68-ga-rm2 is an agent used in diagnostic imaging.

primary objectives: i. to evaluate the feasibility of 68-ga rm2 pet/mri for identification of estrogen receptor positive primary breast cancer and metastases outline: patients receive 68-ga-rm2 intravenously (iv) and after 45 minutes undergo pet/mri over 30-60 minutes. after completion of study, patients are followed up at 24-72 hours, and then for 12 months.

Eligibility criteria:
inclusion criteria: * er+ breast cancer at initial diagnosis prior to surgery or at recurrence (at least one er+ lesion based on results of biopsy). * able to provide written consent * karnofsky performance status of ≥ 50 (or eastern cooperative oncology group (ecog)/world health organization (who) equivalent) exclusion criteria: * less than 18 years-old at the time of radiotracer administration * inability to lie still for the entire imaging time * inability to complete the needed investigational and standard-of-care imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.) * any additional medical condition, serious intercurrent illness, or other extenuating circumstance that, in the opinion of the investigator, may significantly interfere with study compliance * renal function impairment preventing administration of mri contrast * metallic implants (contraindicated for mri)
social cognition and personality changes in alzheimer's & parkinson's disease & frontotemporal lobar degeneration

Conditions: Alzheimer's Disease; Parkinson's Disease; Frontotemporal Lobar Degeneration

Summary: the aim of this study is to compare personality and social cognition changes, including emotion detection and self-awareness, and neuroanatomical correlates in patients, and how that affects the caregiver-patient relationship.

the purpose of this study is to understand social cognition changes in patients with alzheimer's disease (ad), parkinson's disease (pd), and frontotemporal lobar degeneration (ftld), which includes progressive supranuclear palsy (psp), corticobasal syndrome (cbs) and frontotemporal dementia (ftd - behavioural variant frontotemporal dementia, progressive non-fluent aphasia and semantic dementia), and the effect of these changes on the patients' relationship with their caregivers. in addition, the study aims to provide a greater clarity in the neuroanatomical correlates of social cognition in patients with ftld, pd and ad.

Eligibility criteria:
inclusion criteria: patients: * ability to speak and understand the english language (as questionnaires and tests are only available in english) caregivers: * primary caregiver for a given patient * ability to speak and understand the english language (as questionnaires and tests are only available in english) exclusion criteria: patients and caregivers: * history of another neurological disorder * psychiatric disorder * severe aphasia (semantic word loss) * visual deficits requiring correction beyond the use of eyeglasses or contact lenses (intact visual acuity is required for completing both the questionnaires and the emotion evaluation test which consists of video vignettes) * auditory deficits requiring correction beyond hearing aids (videos have auditory component) patients: * presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments or foreign objects in the eyes, skin or body will be excluded as they will be unable to have a mri scan. * premenopausal women will be excluded due to the unknown risk of mris during pregnancy.
prospective clinical assessment study in children with achondroplasia (ach)

Conditions: Achondroplasia

Summary: this is a long-term, multi-center, observational study in children 2.5 to \<17 years with achondroplasia (ach). the objective is to evaluate growth, ach-related medical complications, assessments of health-related quality of life, body pain, functional abilities, cognitive functions, and treatments of study participants. no study medication will be administered.


Eligibility criteria:
key inclusion criteria: * signed informed consent by study participant or parent(s) or legally authorized representative (lar) and signed informed assent by the study participant (when applicable) * aged 2.5 to \<17 years at study entry * diagnosis of ach * study participants and parent(s) or lar(s) are willing and able to comply with study visits and study procedures key exclusion criteria: * have hypochondroplasia or short stature condition other than ach (e.g. trisomy 21, pseudoachondroplasia, psychosocial short stature) * in females, having had their menarche * height \ +2 standard deviations for age and sex based on reference tables on growth in children with ach * annualized height growth velocity ≤1.5 cm/year over a period ≥6 months prior to screening * current evidence of corneal or retinal disorder/keratopathy * current evidence of endocrine alterations of calcium/phosphorus homeostasis * have a concurrent disease or condition that in the view of the investigator and/or sponsor, may impact growth or where the treatment is known to impact growth. * significant abnormality in screening laboratory results. * have been treated with growth hormone, insulin-like growth factor 1 (igf 1), or anabolic steroids in the previous 6 months or long-term treatment (\>3 months) at any time * have had regular long-term treatment (\>1 month) with oral corticosteroids (low-dose ongoing inhaled steroid for asthma is acceptable) * have had previous guided growth surgery or limb-lengthening surgery within 12 months prior to screening.

Keywords: skeletal dysplasia endochondral ossification achondroplasia (ach) shortened proximal limbs fibroblast growth factor receptor 3 fgfr3 endochondral bone formation short-limb disproportionate dwarfism quality of life in achondroplasia dwarfism bone diseases musculoskeletal diseases osteochondrodysplasia genetic diseases inborn functional abilities average growth velocity average height velocity growth congenital